Posted by Michael Wonder on 26 Feb 2025
Pyxis Oncology granted FDA fast track designation for PYX-201 monotherapy in patients with recurrent or metastatic head and neck cancer
26 February 2025 - Pyxis Oncology today announced that the US FDA has granted fast track designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody.
PYX-201 is a first in concept antibody drug conjugate that uniquely targets extradomain-B fibronectin, a non-cellular structural component within the tumour extracellular matrix, which is highly expressed in various tumour types.
